AQST 241220 10.00P (AQST241220P10000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

AQST241220P10000

Watchlist

0.00
0.000.00%

15min DelayClose Dec 3 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Aquestive Therapeutics: Promising FDA Feedback and Solid Foundation Support Buy Rating
TipRanksDec 2 10:35 ET · Ratings
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
Moomoo NewsDec 2 09:31 ET · Ratings
Aquestive Therapeutics Announces DA Feedback And Reaffirms NDA Submission Guidance For Anaphylm Sublingual Film; Confirms No Additional Adult Clinical Trials Are Necessary Prior To NDA Submission
BenzingaDec 2 08:59 ET
Aquestive Therapeutics Gains FDA Support for Anaphylm
TipRanksDec 2 08:28 ET
Express News | Aquestive Therapeutics Inc -Reaffirms New Drug Application (Nda) Q1 2025 Submission Guidance
ReutersDec 2 08:00 ET
Express News | Aquestive Therapeutics Inc -Confirms No Additional Adult Clinical Trials Are Necessary Prior to Nda Submission
ReutersDec 2 08:00 ET

Comments

Trytosaveabit

Dec 2 07:03

Update

$Aquestive Therapeutics (AQST.US)$ Reuters
1 min ago
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms Nda Submission Guidance for Anaphylm™ (Epinephrine) Sublingual Film

FU K D by moo

Nov 13 03:14

I bought in under $2.00, but I'm dumb and "high risk", so I have to close my account and can't wait till AQST pops up to $8-10. Screw me...!

Why does this company cut ties with someone who is doing great in the market and say they're a high risk?
Doesn't make sense to me?

Jaguar8

Oct 25 00:48

Good PR re Epi Sublingual med. Good biotech. Huge float

$Aquestive Therapeutics (AQST.US)$

Jaguar8

Oct 24 07:09

NEWS

$Aquestive Therapeutics (AQST.US)$
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics (NASDAQ: AQST) announced positive topline results from its Oral Allergy Syndrome (OAS) challenge study for Anaphylm™ sublingual film. The study met both primary and secondary endpoints, demonstrating rapid symptom resolution beginning two minutes after administration. The median time for...

Trytosaveabit

Oct 24 07:03

News

$Aquestive Therapeutics (AQST.US)$ Reuters· 1 min ago
Aquestive Therapeutics Inc - Oas Challenge Study Meets Primary and Secondary Endpoints